Sharma, Sanjay <br/><br/>
Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections.  [electronic resource] 

 -  Canadian journal of ophthalmology. Journal canadien d'ophtalmologie  Jun 2012 
 - 275-9 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1715-3360 
<br/><br/><label>Standard No.: </label>10.1016/j.jcjo.2012.03.026  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--adverse effects<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Bevacizumab<br/>Endophthalmitis--epidemiology<br/>Female<br/>Humans<br/>Intravitreal Injections<br/>Macular Edema--drug therapy<br/>Male<br/>Middle Aged<br/>Ranibizumab<br/>Retinal Detachment--epidemiology<br/>Retinal Vein Occlusion--drug therapy<br/>Retrospective Studies<br/>Risk Factors<br/>Thromboembolism--epidemiology<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Visual Acuity<br/>Vitreous Hemorrhage--epidemiology<br/>Wet Macular Degeneration--drug therapy